Analytical performance of the i-stat cardiac troponin I assay
|
|
- Barbara Francine Armstrong
- 5 years ago
- Views:
Transcription
1 Clinica Chimica Acta 345 (2004) Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b, John L. Campbell c, Cary J. Miller c, Karl G. Hock d, Mitchell G. Scott d a Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota School of Medicine, Clinical Labs P4, 701 Park Avenue, Minneapolis, MN 55415, USA b Department of Pathology, University of Maryland, Baltimore, MD, USA c I-STAT Corporation, East Windsor, NJ, USA d Department of Medicine, Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, MO, USA Received 16 January 2004; received in revised form 9 March 2004; accepted 10 March 2004 Abstract Background: This study determines the analytical characteristics of the i-stat cardiac troponin I assay (ctni; i-stat, Princeton, NJ), a 10-min POC assay, designed to be performed at the bedside. Methods: Three different hospitals participated in a patient specimen and analytical validation study (n = 186) for the i-stat ctni assay carried out in real time. A total of 186 whole blood specimens (lithium heparin) were collected from patients presenting with symptoms suggestive of acute coronary syndromes (ACS) for correlation studies as well as from 162 healthy subjects for reference interval determination. Factors studied included antibody specificity, detection limit, imprecision, linearity, assay specificity, sample type stability, interferences, reference limit determination and comparison vs. the Dade Stratus CS ctni assay. Results: Total imprecision (CV) of 10% and 20% were seen at 0.09 and 0.07 Ag/l, respectively. The detection limit was 0.02 Ag/l. The 99th percentile reference limit was 0.08 Ag/l. The assay was not affected by common interferents. An equimolar response within 5% was found for reduced and phosphorylated forms of TIC and IC complexes. Regression analysis for the i-stat ctni between whole blood and plasma specimens and for whole blood between the i-stat and Stratus CS ctni assays demonstrated slopes of 1.06 and 0.89, respectively. Conclusions: The i-stat ctni assay is a sensitive and precise monitor of ctni, poised for point-of-care/near bedside clinical utilization for triage, diagnostics and risk management of acute coronary syndrome patients. D 2004 Elsevier B.V. All rights reserved. Keywords: Myocardial infarction; Cardiac troponin; Point-of-care testing; Emergency medicine 1. Introduction Cardiac troponin (ctn) has been designated as the preferred biomarker for the diagnosis of myocardial injury [1 3]. In the clinical setting of ischemia, the * Corresponding author. Tel.: ; fax: address: fred.apple@co.hennepin.mn.us (F.S. Apple). designation of myocardial infarction (MI) is predicated on an increased ctn above the 99th percentile reference cutoff. In addition, prognosis and risk of death and cardiac events are related in part to the extent of increases of ctn in patients with an ischemic mechanism of injury [4]. Differentiating patients with acute coronary syndromes is predicated on an increased ctn (non-st-elevation MI) and normal ctn (unstable angina) [3]. When the central laboratory is /$ - see front matter D 2004 Elsevier B.V. All rights reserved. doi: /j.cccn
2 124 F.S. Apple et al. / Clinica Chimica Acta 345 (2004) used to monitor biomarkers the American College of Cardiology, American Heart Association, and the National Academy of Clinical Biochemistry have designated that ctn results be available in < 60 min from the time a patient s blood is drawn to reporting of results to the clinician [2,5,6]. Point-of-care (POC)/ near bedside testing systems have been developed to reduce delays in specimen transportation and processing that often occur when cardiac markers are measured in a central laboratory. In addition Emergency Medicine has endorsed the need for rapid turn around of cardiac biomarker testing, specifically cardiac troponin. In chest pain centers, patient triage and therapy management are often reliant upon cardiac troponin findings over the initial 6 to 9 h after presentation in the emergency department [7,8]. Quality specifications that apply to cardiac troponin monitoring using central laboratory instrumentation, including both analytical (antibody selection, calibration to appropriate standards, calculation of limits of detection, interferent studies) and pre-analytical (sample storage effects, specimen types) factors, must also be applied in the assessment of POC ctn assays [9]. The goal of the current study was to determine the analytical characteristics of the i-stat ctni assay (i-stat, Princeton, NJ), a 10-min POC assay, designed to be performed at the bedside. 2. Methods Three different hospital sites as well as i-stat scientists participated in the study. Patient specimen comparisons were performed against the Dade-Behring Stratus CS (Dade-Behring, Newark, DE). Each hospital site carried out the ctni analyses in real time on both analyzers. A total of 186 whole blood specimens (lithium heparin) were collected from patients presenting in the emergency department and cardiology units with symptoms suggestive of acute coronary syndromes (ACS). The determination of the final diagnosis of each patient was not part of this study. Normal healthy volunteers (n = 162) without a known history of heart disease or injury were recruited to donate blood for the normal, reference limit determination. All patients gave informed consent following approval of each site s institutional review board. All whole blood samples (heparinized) were analyzed by non-laboratory personnel (nurses, research assistants) at all three sites within 60 min of collection on the i-stat analyzer. Immediately following whole blood analysis, specimens were centrifuged to separate plasma, and the plasma was then immediately reanalyzed by the same non-laboratory personnel on the i-stat analyzer within 30 min. A separate whole blood tube was also analyzed within1honthestratus CS analyzer, following manufacturer s guidelines [10]. As the comparative device, the Stratus CS ctni assay has been shown to demonstrate the following analytical characteristics: limit of detection 0.03 Ag/ l (mean + 2SD of 20 determinations of the zero calibrator), upper limit of linearity 50 Ag/l, and the concentration at which 10% total imprecision (10% CV) was 0.1 Ag/l. 3. Results The i-stat ctni assay demonstrated a limit of detection (mean + 2SD of 20 replicates of the zero calibrator) at 0.02 Ag/l (mean + 3SD was 0.03 Ag/l) and an upper limit of linearity, determined by serial dilutions of a high ctni plasma specimen, of 50 Ag/l (data not shown). Dilution of whole blood samples is not recommended due to matrix effects. Recovery experiments at approximately 3 Ag/l were 101% to 104%. The monoclonal (capture) and polyclonal (conjugate) antibody paired assay (both directed within the central 30 to 100 amino acids of ctni) demonstrated equimolar response (within 95%) to the following cardiac troponin I forms (obtained from HyTest, Turku Finland): ternary ctnt ctni ctnc (TIC), binary ctni ctnc (IC), and the reduced and phosphorylated forms of TIC and IC. The oxidized form, which was not commercially available, was not tested. In contrast, the relative responses of the Stratus CS to the same ctni isoforms tested ranged from 83% to 121%. Neither citrated nor EDTA whole blood samples were acceptable for analysis due to interference of chelators. Serum was not tested. Based on spiked whole blood specimens, no interferences were found for ctnt, skeletal troponin I isoforms, heterophile antibodies, rheumatoid factors, bilirubin, lipemia, or numerous drugs. Only heparin, at 90 U/ml, was determined to cause substantial interference.
3 F.S. Apple et al. / Clinica Chimica Acta 345 (2004) Total, within-lot and lot-to-lot imprecision over 20 days at concentrations ranging from 0.58 to 33.6 Ag/ l were < 6.1%. ctni cartridges, tested for three different lots, and three concentrations of whole blood control specimens (ctni concentrations of 0.58, 2.38, 4.21 Ag/l ) demonstrated < 4% change stored refrigerated or at room temperature over 14 days. Fig. 1 shows the low-end precision profile in whole blood spiked with the TIC ternary complex, run on 18 i-stat analyzers across three lots of cartridges, performed over 1 day. Each point represents the mean statistics for 18 replicates. The lowest concentration demonstrating a 10% coefficient of variation (CV) was approximately 0.09 Ag/l and a 20% CV was found at approximately 0.07 Ag/l. Regression analysis demonstrated the following equation following removal of 13 specimens with concentrations < 0.02 Ag/l: [i-stat ctni]= 0.89 [Stratus CS ctni] 0.035; r = 0.97; range 0.02 to 36.2 Ag/l (n = 173 whole blood specimens). The 95% confidence intervals for slope and intercept were 0.8 to 0.92 and 0.31 to 0.24, respectively. Regression analysis for the same samples for plasma i-stat vs. whole blood Stratus CS was not significantly different (slope 0.86; intercept 0.032). Regression analysis of the whole blood specimens with ctni concentration < 3 Ag/l demonstrated the following equation: [i-stat ctni] = 0.88 [Stratus CS ctni] 0.036; r = 0.97 (n = 112). An acceptable correlation was also found between the whole blood and plasma paired specimens (n = 173) for the i-stat ctni assay compared across three lots of i-stat ctni cartridges: (whole blood ctni) = 1.06 (plasma ctni) 0.07; r = The 95% confidence intervals for slope and intercept were 1.04 to 1.07 and 0.19 to 0.05, respectively. Fig. 2A and B shows the Bland Altman bias plots for ctni concentrations < 10 Ag/ l(n = 148) for whole blood i-stat vs. whole blood Stratus CS samples, and i-stat whole blood and i-stat plasma samples, respectively. No clinical information was available on any subjects due to IRB restrictions. The 99th percentile reference limit determined (non-parametric statistic) for 162 normal (healthy) volunteers (55% male, 87% Caucasian, age range 23 to 65 years) demonstrated a whole blood cutoff of 0.08 Ag/l and a plasma cutoff of 0.04 Ag/l. One hundred fifty one (93%) normal subjects had concentrations less than the limit of detection ( < 0.02 Ag/l). No specific mechanism can be given to explain the whole blood/plasma difference in 99th percentile limits. However, the assay was insensitive to variations in hematocrit in the range of 0% to 65%; with higher hematocrits exhibiting poor imprecision. 4. Discussion These findings demonstrate acceptable analytical and reference limit characteristics regarding the i- STAT whole blood and plasma POC ctni assay. The Fig. 1. i-stat ctni imprecision profile using whole blood pools.
4 126 F.S. Apple et al. / Clinica Chimica Acta 345 (2004) Fig. 2. Bland Altman bias difference plots for (A) whole blood i-statctni vs. Dade-Behring Stratus CS ctni and (B) i-statwhole blood vs. i-stat heparin plasma ctni. i-stat POC ctni assay was quite close to meeting the ESC/ACC consensus criteria for 10% imprecision at the 99th percentile; demonstrating a ratio of 1.20 [0.09 Ag/l, the lowest concentration to give 10% CV/0.08 Ag/l, the 99th percentile concentration]. These findings complement the total imprecision findings of Panteghini et al. [11], which addresses imprecision profiles of 17 different cardiac troponin assays involving both central laboratory and POC platforms. The 0.07 Ag/l concentration, which demonstrated a 20% CV (functional sensitivity), was < 99th percentile limit. In addition, the 99th percentile whole blood reference limit (0.08 Ag/l) was fourfold above the lowest detection limit (0.02 Ag/l). The few measurable (>limit of detection) ctni concentrations found in normal volunteers cannot be explained as either false positives or true positives, because the current study was not designed to gather clinical information on these subjects. However, these findings are similar to those observed for other cardiac troponin assays in a larger reference range study [12]. These findings will increase the evidence-based literature for implementing the i-stat ctni system along ESC/ACC guidelines [6]. The i-stat ctni assay system was described by users at all three hospital sites as easy to use and provided results 10 min after placing a specimen on a ctni cartridge and initiating analysis on the analyzer; permitting flexibility in use in multiple locations, including cardiac units, emergency departments, chest pain centers, ambulances, and helicopters, as well as in the central laboratory. While a minor negative bias was observed at higher ctni concentrations (Fig. 2A) between the i-stat and Stratus CS, these biases would likely not affect the clinical interpretation for either assay. However, as limited data is available around the 99th percentile limits, and no clinical information was gathered in this study, additional larger studies will be necessary to address this finding. The i-stat system (which measured ctni directly in whole blood without plasma separation) now provides an alternative to quantitative POC troponin assays (such as the Dade-Behring CS, Biosite Triage, Roche Cardiac Reader, all of which separate plasma from cells prior to ctn analysis) as well as qualitative cardiac troponin assays (Spectral Diagnostics, Roche Cardiac). These claims are supported by the fact that the non-laboratory healthcare workers (nurses, assistants) in cardiac units and emergency departments performed the i-stat whole blood analyses for patients and controls in the current study. While serum was not tested in the present study, decreased concentrations have been observed in heparinized plasma compared with serum due to direct molecular interaction between ctni and heparin [13,14]. Therefore, for any ctni or ctnt assay system, whether point-of-care or central laboratory, direct comparison should be carried out between serum and heparinized plasma to validate potential biases. In conclusion, the i-stat assay system (FDA cleared) is now poised for patient care use in emergency departments, chest pain centers, cardiology
5 F.S. Apple et al. / Clinica Chimica Acta 345 (2004) units as well as in central laboratories. Patient-based clinical studies, including diagnostics for detection of MI, risk outcomes assessment in ACS patients, and outcome studies in non-ischemic myocardial injury pathologies, are needed for this point-of-care, rapid ctni assay, to provide the evidence-based support for management of acute coronary syndrome patients in emergency department practice utilizing POC testing systems [7,8]. Acknowledgements This work was supported in part by i-stat. References [1] Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It s time for a change to a troponin standard. Circulation 2000;102: [2] The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: [3] Braunwald E, for the committee on the management of patients with unstable angina. ACC/AHA guidelines for the management of patients with unstable angina and non-stsegment elevation myocardial infarction. J Am Coll Cardiol 2000;36: [4] Ottani F, Galvani M, Nicolini FA, Ferrini D, Pozzati A, DiPasquele G, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140: [5] Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw NM, Valdes Jr R. National Academy of Clinical Biochemistry Standards of laboratory practice: recommendations for use of cardiac markers in coronary artery diseases. Clin Chem 1999;45: [6] Apple FS, Wu AHB, Jaffe AS. Implementation of the ESC/ ACC guidelines for redefinition of myocardial infarction using cardiac troponin assays with special attention to clinical trial issues. Am Heart J 2002;144: [7] Blomkans AL, Gibler WB. It s about time: the evolution of acute coronary syndrome evaluation in the emergency department. Ann Emerg Med 2002;40: [8] Pollack CV, Roe MT, Peterson ED Update to ACC/ AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 2003;41: [9] Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AHB. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001;39: [10] Heeschen C, Goldmann BU, Langenbrink L, Matschuck G, Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with chest pain. Clin Chem 1999;45: [11] Panteghini M, Pagani F, Yeo JKT, Apple FS, Christenson RH, Dati F, et al. Evaluation of the imprecision at low-range concentrations of the assays for cardiac troponin determination. Clin Chem 2004;50: [12] Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB for use with ESC/ACC consensus recommendations. Clin Chem 2003;49: [13] Gerhardt W, Nordin G, Herbert AK, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared to serum: lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000;46: [14] Speth M, Seibold K, Katz N. Interaction between heparin and cardiac troponin T and troponin I from patients after coronary bypass surgery. Clin Chem 2002;35:
Papers in Press. Published March 23, 2007 as doi: /clinchem
Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)
More informationArticle in press - uncorrected proof
Clin Chem Lab Med 2006;44(6):768 773 2006 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2006.125 2006/60 Integration between the Tele-Cardiology Unit and the central laboratory: methodological
More informationP1: OTE/SPH P2: OTE BLUK084-Adams April 13, :13 PART 1. Cardiac troponins
PART 1 Cardiac troponins 1 2 CHAPTER 1 Basics of cardiac troponin: practical aspects of assays, potential analytical confounders, and clinical interpretation Fred S. Apple Case 1 Following an episode of
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationWaiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad
Waiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad Fred Apple PhD Hennepin County Medical Center University of Minnesota
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationAbout OMICS International
About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700
More informationEvaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain
Clinical Chemistry 45:10 1789 1796 (1999) Enzymes and Protein Markers Evaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain Christopher Heeschen, 1*
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationLower Cardiac Troponin T and I Results in Heparin-Plasma Than in Serum
Clinical Chemistry 46:9 1338 1344 (2000) Enzymes and Protein Markers Lower Cardiac Troponin T and I Results in Heparin-Plasma Than in Serum Hugo Stiegler, 1* Yuriko Fischer, 1 Jaime F. Vazquez-Jimenez,
More information13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS
13. RECOMMENDATIONS ON USE OF BIOCHEMICAL MARKERS IN ACUTE CORONARY SYNDROME: IFCC PROPOSALS Prof. Mauro Panteghini, MD, Ph.D. Chairman of the IFCC Committee on Standardization of Markers of Cardiac Damage
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationFrequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062
More informationOriginal Article Decision limit for troponin I and assay performance Abstract Address Background Correspondence Methods Results Conclusions
Decision limit for troponin I and assay performance Paul Sheehan, John Blennerhassett and Samuel D Vasikaran Original Article Abstract Address Core Clinical Pathology and Biochemistry Division of Laboratory
More informationCARDIAC TROPONIN I/ (ctni)
CARDIAC TROPONIN I/ (ctni) Intended Use The i-stat cardiac troponin I (ctni) test is an in vitro diagnostic test for the quantitative measurement of cardiac troponin I (ctni) in whole blood or plasma.
More informationPeter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S.
Clinical Chemistry 52:11 2028 2035 (2006) Evidence-Based Laboratory Medicine and Test Utilization Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationT he World Health Organization defined myocardial infarction
343 CARDIOVASCULAR MEDICINE Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction J L Ferguson, G J Beckett, M Stoddart,
More informationCREATINE KINASE MB/ (CK-MB)
CREATINE KINASE MB/ (CK-MB) Intended Use The i-stat CK-MB test is an in vitro diagnostic test for the quantitative measurement of creatine kinase MB mass in whole blood or plasma samples. CK-MB measurements
More informationRapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.
Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD
More informationGUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT
GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT sponsored by TROPONIN OVERVIEW TROPONIN DETECTION IN NORMAL AND DISEASE STATES1 The detection of
More informationTroponin I Measurement: Evolution of a Biomarker Essential for Assessment of Myocardial Injury
Troponin I Measurement: Evolution of a Biomarker Essential for Assessment of Myocardial Injury Robert H. Christenson, Ph.D., DABCC, FACB Professor of Pathology Professor of Medical and Research Technology
More informationComparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology
Journal of Health Sciences www.jhsci.ba Volume 1, Number 3, December 2011 Comparison of ARCHITECT chemiluminiscent microparticle immunoassay for determination of Troponin I in serum with AXYM MEIA technology
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationACUTE MYOCARDIAL INFARCTION: DEFINITION, DIAGNOSIS, AND THE EVOLUTION OF CARDIAC MARKERS
ACUTE MYOCARDIAL INFARCTION: DEFINITION, DIAGNOSIS, AND THE EVOLUTION OF CARDIAC MARKERS d Copyright 2018 by. LEARNING OBJECTIVES: 1. Define MI and the challenges in MI diagnosis 2. Define the current
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationComparative assessment of rapid test and routinmethods th to measurement of cardiac markers in patients with acute chest pain
Comparative assessment of rapid test and routinmethods th to measurement of cardiac markers in patients with acute chest pain *Reza Shahsavari I, Nastou Dehkourdi II and Saeid Yazdankha III I ) Assistant
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationCardiac Bio-Marker Testing in Acute Coronary Syndromes
Cardiac Bio-Marker Testing in Acute Coronary Syndromes Dr. Zohair Alaseri, MD FRCPc, Emergency Medicine FRCPc, Critical Care Medicine Intensivest and Emergency Medicine Consultant Chairman, Department
More informationEvaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)
Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on CUBE analyser (CA0100) Location Location: Eurolyser Diagnostica GmbH Operators: Simone Wieser; Franz Helminger; Michael Gruber Date: July-November
More informationThe Clinical Laboratory Working with Physicians to Improve Patient Care
The Clinical Laboratory Working with Physicians to Improve Patient Care Michael A. Pesce, PhD Professor Emeritus Columbia University Medical Center Department of Pathology and Cell Biology Objectives Troponin
More informationCardiac Troponin: Current Status and Future Promise
Cardiac Troponin: Current Status and Future Promise Robert H. Christenson, Ph.D., ABCC, FACB Professor of Pathology Professor of Medical and Research Technology University of Maryland School of Medicine
More informationChapter 2. High-sensitivity C-reactive protein methods examined
Chapter High-sensitivity C-reactive protein methods examined Snježana Rothkrantz-Kos, Maria PJ Schmitz, Otto Bekers, Paul PCA Menheere, Marja P van Dieijen-Visser Clin Chem ;48:359-6 3 Chapter Abstract
More informationJMSCR Vol 05 Issue 01 Page January 2017
JMSCR Vol Issue Page 93-943 January 27 www.jmscr.igmpublication.org Impact Factor.84 Index Copernicus Value: 83.27 ISSN (e)-2347-76x ISSN (p) 24-4 DOI: https://dx.doi.org/.83/jmscr/vi.3 Elevation of Troponin-I
More informationThe state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T
Editorial Page 1 of 5 The state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T Aldo Clerico 1, Giuseppe Lippi 2 1 Scuola Superiore Sant Anna and Fondazione CNR Regione
More informationChallenging Issues in Cardiac Biomarker interpretation. F. Nikaeen. MD interventional Cardiologist
Challenging Issues in Cardiac Biomarker interpretation F. Nikaeen. MD interventional Cardiologist Biomarkers Types of Troponin Troponin C Binds calcium Troponin I Binds actin Troponin T Binds tropomyosin
More informationProcedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test. Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature
Procedures: LifeSign MI Myoglobin/CK-MB/Troponin I Test Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE:
More informationEvaluation in an emergency department of rapid separator tubes containing thrombin for serum preparation prior to hs-ctnt and CK-MB analyses
Budak et al. BMC Clinical Pathology 2013, 13:20 RESEARCH ARTICLE Open Access Evaluation in an emergency department of rapid separator tubes containing thrombin for serum preparation prior to hs-ctnt and
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number: k100322 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE B. Purpose for Submission: Clearance of a new device C. Measurand: Whole
More informationcobas h 232 POC system The power to make decisions in cardiac emergencies
cobas h 232 POC system The power to make decisions in cardiac emergencies cobas h 232 POC system Rapid results at the Point of Care (POC) Wherever and whenever you face an emergency situation, measurement
More informationHuman Troponin I ELISA Kit
Human Troponin I ELISA Kit Cat. No.:DEIA2358 Pkg.Size:96T Intended use This kit is intended for the quantitative determination of cardiac troponin I in human serum. Measurement of troponin I values are
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationNational Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases
Clinical Chemistry 45:7 1104 1121 (1999) NACB National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases Alan
More informationA 45-Year-Old Man with Substantial Chest Pain
Case 1 A 45-Year-Old Man with Substantial Chest Pain Fred S. Apple History of Current Presentation The subject is a 45-year-old African-American male who presents with a chief complaint of substantial
More informationFor In Vitro Diagnostic use within the United States of America. This product is for Research Use Only outside of the United States of America.
Troponin I ELISA For the quantitative determination of cardiac troponin I in human serum. For In Vitro Diagnostic use within the United States of America. This product is for Research Use Only outside
More informationComparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration
Clinical Chemistry / Whole Blood Creatinine for egfr Comparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration Nichole
More informationClinical Investigations
Clinical Investigations The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-Segment Elevation Acute Coronary Syndrome: Results from CRUSADE Address for
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationStatistical Considerations: Study Designs and Challenges in the Development and Validation of Cancer Biomarkers
MD-TIP Workshop at UVA Campus, 2011 Statistical Considerations: Study Designs and Challenges in the Development and Validation of Cancer Biomarkers Meijuan Li, PhD Acting Team Leader Diagnostic Devices
More informationRecent advances in point-of-care diagnostics
Alan H.B. Wu In this Issue: Focusing on POCT Recent advances in point-of-care diagnostics for cardiac markers Alan H.B. Wu, Ph.D. Department of Laboratory Medicine, University of California, San Francisco
More informationRuling out acute myocardial infarction early with two serial creatine kinase-mb mass determinations
European Heart Journal (1999) 20, 967 972 Article No. euhj.1998.1449, available online at http://www.idealibrary.com on Ruling out acute myocardial infarction early with two serial creatine kinase-mb mass
More informationLow concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationMost patients ( 85%) who present to an emergency department
Ninety-Minute Exclusion of Acute Myocardial Infarction By Use of Quantitative Point-of-Care Testing of Myoglobin and Troponin I James McCord, MD; Richard M. Nowak, MD, MBA; Peter A. McCullough, MD, MPH;
More informationG / R11 B2K4Y0. ARCHITECT STAT Troponin-I. STAT Troponin-I 2K41 2K K41-37
ARCHITECT STAT Troponin-I Read Highlighted Changes: Revised June 2015. 2K41-27 2K41-37 en STAT Troponin-I 2K41 G1-0467 / R11 B2K4Y0 Package insert instructions must be carefully followed. Reliability of
More informationConference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications
Conference Papers in Medicine, Article ID 583175, 5 pages http://dx.doi.org/10.1155/2013/583175 Conference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction:
More informationProduct Information. Instruction for Use. Troponin I ELISA kit Catalog Number: EA Storage Temperature: 2 8 C
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com Product Information Troponin I ELISA kit Catalog Number:
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationAvailable online at
152 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 2, 2015 The Distribution of Abbott High-Sensitivity Troponin I Levels in Korean Patients with Chest Pain
More informationDetermination of hemoglobin is one of the most commonly
ORIGINAL ARTICLE Multiple-Site Analytic Evaluation of a New Portable Analyzer, HemoCue Hb 201+, for Point-of-Care Testing Sten-Erik Bäck, PhD,* Carl G. M. Magnusson, PhD, Lena K. Norlund, MD, PhD, Henning
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationLIPASE liquicolor. Design Verification. Multipurpose Reagent
Design Verification LIPASE liquicolor Multipurpose Reagent CONTENTS 1 Introduction... 2 2 Imprecision... 2 3 Linearity and Detection Limit... 2 3.1 Linearity... 2 3.2 Detection Limit... 3 4 Recovery of
More informationTROPONIN I (HUMAN CARDIAC-SPECIFIC) ENZYME IMMUNOASSAY TEST KIT Catalog Number: 11050
FOR INFORMATIONAL USE ONLY DO NOT USE FOR PERFORMING ASSAY REFER TO MOST CURRENT PACKAGE INSERT ACCOMPANYING TEST KIT TROPONIN I (HUMAN CARDIAC-SPECIFIC) ENZYME IMMUNOASSAY TEST KIT Catalog Number: 11050
More informationMarkers. Clinical Chemistry 46: (2000) Enzymes and Protein
Clinical Chemistry 46:6 817 821 (2000) Enzymes and Protein Markers Troponin T and I Assays Show Decreased Concentrations in Heparin Plasma Compared with Serum: Lower Recoveries in Early than in Late Phases
More informationCardiovascular disease is the leading cause of morbidity
Cardiac Troponin I Predicts Short-Term Mortality in Vascular Surgery Patients Lauren J. Kim, MPH; Elizabeth A. Martinez, MD; Nauder Faraday, MD; Todd Dorman, MD; Lee A. Fleisher, MD; Bruce A. Perler, MD;
More informationTopic. Updates on Definition of Myocardial Infarction
Topic Updates on Definition of Myocardial Infarction In the past, general consensus for MI? Definition of MI by WHO - Combination of 2 of 3 characteristics - 1. Typical Symptoms 2. Enzyme Rise 3. Typical
More informationJournal of the American College of Cardiology Vol. 40, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02119-8
More informationASSESSMENT OF A POINT-OF-CARE DEVICE FOR MEASURING CREATININE IN A COMMUNITY SCREENING PROGRAM FOR CHRONIC KIDNEY DISEASE
ASSESSMENT OF A POINT-OF-CARE DEVICE FOR MEASURING CREATININE IN A COMMUNITY SCREENING PROGRAM FOR CHRONIC KIDNEY DISEASE Brooke Ann Spaeth, Anne K Shephard, Mark DS Shephard, Timothy H Mathew ABSTRACT
More informationSafe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB mass
Heart 2001;85:143 148 143 Department of Cardiology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands R Bholasingh R J de Winter J C Fischer R W Koster RJGPeters G T Sanders Correspondence
More information1. PROTOCOL. Comparison Study Summary. Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR July 30, 2014
Comparison Study Summary Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR 97123 July 30, 2014 1. PROTOCOL This study was conducted on July 24 th, 2014 at Tuality Healthcare, Hillsboro, OR. The
More informationUSING THE ACCESS AMH ASSAY IN YOUR LABORATORY
INFORMATION BULLETIN USING THE ACCESS AMH ASSAY IN YOUR LABORATORY ///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
More information9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation
Disclosures Cardiac Troponin: ER Utilization and the Next Generation Joshua Soldo is an employee of Roche Diagnostics within the division of Medical Scientific Affairs. Data presented is intended for purely
More informationInterpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness
Clinica Chimica Acta 333 (2003) 209 219 www.elsevier.com/locate/clinchim Interpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness
More informationTROPONIN I (HUMAN CARDIAC-SPECIFIC) ENZYME IMMUNOASSAY TEST KIT Catalog Number: EA101005
TROPONIN I (HUMAN CARDIAC-SPECIFIC) ENZYME IMMUNOASSAY TEST KIT Catalog Number: EA101005 Enzyme Immunoassay for the Quantitative Determination of Cardiac-Specific Troponin-I in Human Serum FOR IN VITRO
More informationGlucose Analytical Comparability Evaluation of the YSI 2300 STAT Plus and YSI 2900D Biochemistry Analyzers
Glucose Analytical Comparability Evaluation of the YSI 2300 STAT Plus and YSI 2900D iochemistry Analyzers Life Sciences Data for Life. TM YSI Life Sciences White Paper 91 Authors: Kevin Schlueter, PhD,
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationBIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.
BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS As. MARUSHCHAK M.I. Heart attack symptoms Acute MI Measurement of cardiac enzyme levels Measure cardiac enzyme levels at regular
More informationTotal Thyroxine ELISA (T4)
Design Verification Total Thyroxine ELISA (T4) Contents 1 Assay Principle... 2 2 Imprecision... 2 Within-run Imprecision... 2 Between run Imprecision... 2 3 Comparison of Methods, Accuracy... 2 4 Linearity...
More information2000 The European Society of Cardiology
European Heart Journal (2000) 21, 1502 1513 doi:10.1053/euhj.2000.2305, available online at http://www.idealibrary.com on Consensus Document Myocardial infarction redefined A consensus document of The
More informationEarly diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong
Hong Kong Journal of Emergency Medicine Early diagnosis of acute myocardial infarction by bedside multimarker test at an emergency department in Hong Kong CH Ho, W Cheng, G Chu, HF Ho Introduction: Cardiac
More informationGentian Canine CRP Immunoassay Application Note for Abbott Architect * c4000
v2-jan214 Gentian Canine CRP Immunoassay Application Note for Abbott Architect * c4 Intended Use The canine CRP immunoassay on Abbott's Architect c4 is an in vitro diagnostic test for quantitative determination
More informationThe New England Journal of Medicine
EMERGENCY ROOM TRIAGE OF PATIENTS WITH ACUTE CHEST PAIN BY MEANS OF RAPID TESTING FOR CARDIAC TROPONIN T OR TROPONIN I CHRISTIAN W. HAMM, M.D., BRITTA U. GOLDMANN, M.D., CHRISTOPHER HEESCHEN, M.D., GEORG
More information2019 Reference Manual Updates
2019 Reference Manual Updates (January 2019 to date) The enclosed Client Grams include updated and supplemental information to our most recently published Reference Manual (2019) and are intended to be
More informationJournal of the American College of Cardiology Vol. 36, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00897-4 A Randomized
More informationTYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
More informationCardiac-specific troponin I (ctni) has been under intensive
Original Articles Association of Mild Transient Elevation of Troponin I Levels With Increased Mortality and Major Cardiovascular Events in the General Patient Population G. Steinar Gudmundsson, MD; Stephen
More informationFalse Positive Cardiac Troponin Results in Patients Without Acute Myocardial Infarction
Received 2.16.06 Revisions Received 3.15.06 Accepted 3.21.06 False Positive Cardiac Troponin Results in Patients Without Acute Myocardial Infarction Gifford Lum, MD, 1 David E. Solarz, MD, 2 Linda Farney,
More informationAssociation of Cardiac Troponin, CK-MB, and Postoperative Myocardial Ischemia With Long-Term Survival After Major Vascular Surgery
Journal of the American College of Cardiology Vol. 42, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)01069-6
More information